Anti-Avelumab (Bavencio®) (Human) ELISA Kit

Product Overview

A Sandwich ELISA kit for the qualitative determination of antibody against Avelumab in human serum or plasma.

Avelumab (Bavencio®) is a fully human anti-PD-L1 IgG1 lambda monoclonal antibody that has a molecular weight of approximately 147 kDa. Avelumab binds PD-L1 and blocks the interaction between PD-L1 and its receptors PD-1 and B7-1. By inhibiting PD-L1 interactions, avelumab is thought to enable the activation of T-cells and the adaptive immune system. By retaining anative Fc-region, avelumab is thought to engage the innate immune system and may induce antibody-dependent cell-mediated cytotoxicity. Importantly, avelumab has not shown antibody-dependent cell mediated cytotoxicity against immune cell subsets in humans. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. 96Trace’s anti-Avelumab ELISA kit is designed to detect antibody against Avelumab with high specificity and sensitivity in biological matrices.

Assay Information

Applications

This ELISA kit is used for Qualitative determination of antibody against Avelumab (Bavencio) in serum and plasma

Features & Benefits

• Easy, convenient, sensitive and time-saving method toqualitative determination of antibody against Avelumab (Bavencio) in human serum and plasma.
• Cross Reactivity: Avelumab (Bavencio®) infusion camouflages/masks the presence of antibody to Avelumab in serum/plasma samples. Therefore, blood sampling time is critical for detection of antibody to Avelumab. It is convenient to obtain blood sample just before the infusion or at least 2 weeks after the infusion of Pembrolizumab.

Storage & Shipping

Product Details